Long Island University Arnold and Marie Schwartz College of Pharmacy and Health Sciences | United States
Assist. Prof. Dr. Avinash Kumar, Ph.D., is an Assistant Professor at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY. With a Ph.D. in Biotechnology from the University of Pune, India, his doctoral work focused on biochemical and biophysical characterization of class II α-mannosidases. He completed postdoctoral research at the University of Mississippi Medical Center and National Center for Cell Science, India, investigating transcriptional and post-translational programs driving prostate cancer progression. His research aims to develop personalized and precision medicine strategies targeting metastatic and high-risk prostate cancer, including health disparities in African American men. Dr. Kumar utilizes high-throughput single-cell genomics, transcriptomics, and proteomics in combination with genetically engineered and xenograft mouse models, patient tissues, and complementary cell line studies. He has mentored numerous graduate, undergraduate, and Pharm.D. students, directed the Molecular Imaging Core at LIU, and actively serves on institutional committees and as a reviewer for top journals. Dr. Kumar has published 28 peer-reviewed articles, 5 book chapters, and over 20 conference abstracts, with an h-index of 17 , 873 citations, and 29 publications. He has received multiple fellowships, awards, and research grants and continues to advance translational cancer therapeutics through rigorous preclinical and mechanistic studies.
Featured Publications
“Reprogrammed Lipid Metabolism-Associated Therapeutic Vulnerabilities in Prostate Cancer”
“The Therapeutic Efficacy and Mechanism of Action of Gnetin C, a Natural Compound from the Melinjo Plant, Preclinical Mouse Model of Advanced Prostate Cancer”
“AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for development of cancer therapeutics”
“Data from Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer”
“Supplementary Figure 1-2; Supplementary Table 1-4 from Dietary Pterostilbene for MTA1-Targeted Interception in High- Risk Premalignant Prostate Cancer”